Hydrops and fetal hypoplastic left heart: An unexpected improvement after cessation of maternal polysubstance abuse

Chevalier, Geoffroy; Rakza, Thameur; Joriot, Sylvie; Gautier, Sophie; Houfflin‐Debarge, V.

doi:10.1016/j.jogoh.2018.09.002

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of publications included in this review were the 14 case reports for lacosamide. 18–31 The other publications on lacosamide included nine case series, 32–40 one retrospective cohort study, 41 and two pharmacovigilance safety reports. 42,43…”

Section: Resultsmentioning

confidence: 99%

“…The majority of publications included in this review were the 14 case reports for lacosamide. [18][19][20][21][22][23][24][25][26][27][28][29][30][31] The other publications on lacosamide included nine case series, [32][33][34][35][36][37][38][39][40] one retrospective cohort study, 41 and two pharmacovigilance safety reports. 42,43 Ben-Menachem et al reported in a multicenter open-label trial that two individuals became pregnant.…”

Section: Synthesis Of Results From Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review

Goubran,

Okunnu,

Lavu

et al. 2024

Science Progress

View full text Add to dashboard Cite

Background: Third generation antiseizure medications (ASMs) are currently used for seizure control as well as several other indications, including pain management and psychiatric disorders. As a result, maternal exposure to third generation ASMs during pregnancy has become increasingly prevalent. The current systematic review aimed to summarize the published evidence on third generation ASMs and their effect on preterm birth, cesarean section (c-section) and fetal loss. Methods: The following databases were searched: Medline, Embase, International Pharmaceutical Abstracts, Cochrane Library and Scopus until September 2022. Results: We screened 2987 studies, and identified 32 studies or case reports for inclusion, however only one study utilized a control group. Narrative systematic evidence synthesis was conducted for brivaracetam, eslicarbazepine, fosphenytoin, lacosamide and perampanel. Conclusion: Due to the scarcity and quality of published studies, drawing clear-cut conclusions regarding third generation ASMs and the outcomes of interest is challenging. More comparative safety studies focusing on neonatal safety of third generation ASMs in pregnancy are essential.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Synthesis Of Results From Included Studiesmentioning

confidence: 99%

Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review

Goubran,

Okunnu,

Lavu

et al. 2024

Science Progress

View full text Add to dashboard Cite

show abstract

“…A promising case report described a good postoperative recovery of a newborn that underwent a surgical procedure with resection of the coarcting zone and anastomosis [49]. A fetal ultrasound examination was helpful to detect probable fetal alcohol syndrome, fetal abnormalities, and growth retardation.…”

Section: Discussionmentioning

confidence: 99%

“…A fetal ultrasound examination was helpful to detect probable fetal alcohol syndrome, fetal abnormalities, and growth retardation. Despite the favorable cardiac and hemodynamic the neurodevelopmental prognosis of this child remained uncertain because of fetal alcohol syndrome and exposure to several toxins [49]. In such complex cases, the child's psychoneurological development often remains disturbed and requires long-term monitoring and treatment as well as psychosocial support.…”

Section: Discussionmentioning

confidence: 99%

Fetal Alcohol Spectrum Disorders and Inadequacy of Care: Importance of Raising Awareness in Clinical Practice

Lesinskienė,

Žilinskas,

Utkus

et al. 2023

Children

View full text Add to dashboard Cite

Prenatal alcohol exposure is one of the major avoidable causes of developmental disruption and health abnormalities in children. Fetal alcohol spectrum disorders (FASDs), a significant consequence of prenatal alcohol exposure, have gained more attention recently. This review aims to provide a narrative approach to the scientific literature on the history, clinical presentation, diagnosis, and management of FASDs. A literature search in PubMed, ScienceDirect, and Google Scholar online databases was conducted. The dates of publications ranged from 2000 to 2023. FASD presentations tend to persist into adulthood, which, combined with environmental factors, potentially lead to secondary psychosocial problems and disabilities. This review covers different aspects of FASDs regarding the concept of the umbrella term and public health, somatic, and psychiatric perspectives. FASD management remains an obstacle to health professionals, and mental health problems are underestimated. Its management involves a multi-disciplinary team, which varies according to the patient’s individual needs. FASD diagnosis and management have not been sufficiently established and tailored. Stigma, cultural contexts, knowledge gaps, and the heterogeneity of clinical manifestations are significant barriers to an accurate diagnostic process. Further development of early interventions and the elaboration of complex treatment approaches are needed.

show abstract

Lacosamide

2019

Reactions Weekly

View full text Add to dashboard Cite

Hydrops and fetal hypoplastic left heart: An unexpected improvement after cessation of maternal polysubstance abuse

Cited by 3 publications

References 13 publications

Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review

Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review

Fetal Alcohol Spectrum Disorders and Inadequacy of Care: Importance of Raising Awareness in Clinical Practice

Lacosamide

Contact Info

Product

Resources

About